

ERRATUM

Catia Marzolini · Laurent A. Decosterd · Fei Shen
 Marc Gander · Serge Leyvraz · Jean Bauer
 Thierry Buclin · Jérôme Biollaz · Ferdy Lejeune

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

In: Cancer Chemother Pharmacol (1998) 42: 433–440

In the Reference section of the above paper on p. 440 Reference no. 10 (Khayat et al.) was erroneously omitted when the authors' corrections were carried out. The subsequent numbering was erroneously changed as well. Thus, the reference numbers (starting with Ref. no. 10) are mismatched with the reference titles and cannot be identified in the paper itself. The correct list of References and numbers should read as follows:

References

10. Khayat D, Lokiec F, Bizzani JP, Weil M, Meeus L, Sellani M, Rouesse J, Bonzet P, Jacquillant C (1987) Phase I clinical study of the new amino acid-linked nitrosourea, S10036, administered on a weekly schedule. *Cancer Res* 47: 6782–6785
11. Kleeberg UR, Engel E, Israels P, Brocker EB, Tilgen W, Kennes C, Gerard B, Lejeune F, Glabbeke MV, Lentz MA (1995) Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumor load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). *Melanoma Res* 5: 195–200
12. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP (1994) Fotemustine in the treatment of brain primary tumors and metastases. *Cancer Invest* 12: 414–420
13. Lee SM, Margison GP, Woodcock AA, Thatcher N (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. *Br J Cancer* 67: 1356–1360
14. Aamdal S, Gerard B, Bohman T, D'Incalci M (1992) Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma – an effective combination with unexpected toxicity. *Eur J Cancer* 28: 447–450
15. Gerard B, Aamdal S, Lee S, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP (1993) Activity and unexpected lung toxicity of the sequential administration of two alkylating agents – dacarbazine and fotemustine – in patients with melanoma. *Eur J Cancer* 5: 711–719
16. Tsang LLH, Farmer PB, Gescher A, Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. *Cancer Chemother Pharmacol* 26: 429–436
17. Newlands ES, Blackledge GRP, Slack JA, Rustin CSS, Smith DB, Stuart NSA, Quaterman CP, Hoffman R, Stevens MFG, Brompton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). *Br J Cancer* 65: 287–291
18. O'Reilly SM, Newlands ES, Glaser MG, Brompton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. *Eur J Cancer* 29A: 940–942
19. Dhodapkar M, Reid J, Ames J, Buckner MM, Burch JC, Rubin PA (1994) Phase I clinical trial and pharmacokinetics of temozolomide (NSC 362856). *Proc Am Assoc Cancer Res* 35: 463
20. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GIS, Brompton M, Stevens MFG (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. *J Clin Oncol* 13: 910–913
21. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brompton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. *Eur J Cancer* 32A: 2236–2241
22. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties. Pre-clinical development and clinical trials. *Cancer Treat Rev* 23: 35–61

C. Marzolini¹ · L.A. Decosterd (✉) · F. Shen²

T. Buclin · J. Biollaz

Division de Pharmacologie Clinique,
 BH18-218, Département de médecine,
 Centre Hospitalier Universitaire Vaudois,
 rue du Bugnon 46, CH-1011 Lausanne, Switzerland
 e-mail: Laurent.arthur.Decosterd@chuv.hospvd.ch
 Tel.: +41-21-314 42 72; Fax: +41-21-314 42 88

M. Gander · S. Leyvraz · J. Bauer · F. Lejeune
 Centre Pluridisciplinaire d'Oncologie,
 Centre Hospitalier Universitaire Vaudois,
 rue du Bugnon 46, CH-1011 Lausanne, Switzerland

Present addresses:

¹ SOS Pharmaciens, rue des Cordiers 4,
 CH-1207 Geneva, Switzerland

² Laboratory for Experimental Oncology,
 RR 337, Indiana University School of Medicine,
 702 Barnhill Drive, Indianapolis, IN 46202-5119, USA

23. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollaz J, Lejeune FJ (1995) Determination of temozolomide in human plasma and urine by high performance liquid chromatography after solid phase extraction. *J Chromatogr [B]* 665: 291–300
24. WHO (1919) Handbook for reporting results of cancer treatment. Offset publication 48, WHO, Geneva
25. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumour xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Res* 54: 3793–3799
26. Mitchell RB, Dolan ME (1993) Effect of temozolomide and dacarbazine on O⁶-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Chemother Pharmacol* 32: 59–63
27. Statkevich P, Judson I, Cutler D, Dugan M, Salfi M, Batra V, Reidenberg P (1997) Effect of ranitidine on the pharmacokinetics of temozolomide. *Clin Pharmacol Ther* 61: 39, 147
28. Kerr DJ, Los G (1993) Pharmacokinetic principles of locoregional chemotherapy. *Cancer Surv* 17: 105–119
29. Fety R, Lucas C, Solere P, Cour V, Vienoud J (1992) Hepatic intra-arterial infusion of fotemustine: pharmacokinetics. *Cancer Chemother Pharmacol* 31: 118–122
30. Patel M, McCully C, Godwin K, Balis F (1995) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. *Proc Am Soc Clin Oncol* 14: 461
31. Lee SM, Thatcher N, Growther D, Margison GP (1994) Inactivation of O⁶-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. *Br J Cancer* 69: 452–456